Drug class

The GIP/GLP-1 class

GIP/GLP-1 medications, with sourced prices, shortage reports and study results.

Last checked · Oct 3, 2026 UTC

1approved

1in development

Approved in this class

Alphabetical by active ingredient. Approved uses depend on the specific brand and formulation.

GIP/GLP-1

Tirzepatide

Mounjaro, Zepbound

Subcutaneous injection · Once weekly

FDA shortage report

Published entry quote

$299-$449/28 days

Zepbound KwikPen (multi-dose pen) · LillyDirect (Eli Lilly)

Checked Sep 30, 2026

Price conditions

self-pay cash, by dose ($299 / $399 / $449)

Four weekly doses per pen; pen needles must be purchased separately. $299 at 2.5 mg, $399 at 5 mg, and $449 at higher doses under the Self Pay Journey offer with a refill within 45 days.

28-day supply

Checked Sep 30, 2026. Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Investigational (pipeline)

Alphabetical by active ingredient. These entries are not FDA-approved for this category; open a record for the studied uses and evidence.

GIP/GLP-1Phase 3

VK2735

VK2735 (investigational)

Subcutaneous injection (oral tablet in development) · Once weekly (injectable); once daily (oral)

Investigational. No FDA-approved purchase option.

Study evidence & development

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.